Long-term PSA screening trials now show a prostate cancer mortality benefit with high certainty

Design

Systematic review and meta-analysis of randomised trials, GRADE assessed

Population

5 trials, 721,607 men aged 45–80, 11–23 years' follow-up

Primary outcome

Prostate cancer-specific mortality at longest follow-up

Effect

Reduced with screening (p<0.001), high certainty; larger relative reduction with longer follow-up

This systematic review pooled five randomised trials of PSA-based screening against no screening or usual care, involving 721,607 men aged 45 to 80, with 11 to 23 years of follow-up. It estimated the effect among men who actually took part in screening, and graded certainty with GRADE.

Screening reduced prostate cancer mortality at the longest follow-up, with high-certainty evidence, and the relative reduction appeared larger the longer men were followed. The authors note that differing protocols and screening in control arms probably made the benefit look smaller than it is. The abstract does not give the pooled rate ratio.

This contrasts with earlier reviews that found the evidence uncertain. The authors are explicit that it does not by itself justify population screening: overdiagnosis, biopsy complications and treatment harms remain, and each man's decision should weigh them. For Indian practice, where there is no organised prostate screening programme, the result supports shared decision-making with informed men rather than routine PSA testing in everyone. It was published in May 2026.

• Discuss PSA screening with men who ask, explaining the mortality benefit and the risks of overdiagnosis and treatment.
• Do not order PSA as a routine test without that discussion.
• The benefit appeared larger with longer follow-up, so it is most relevant to men with long life expectancy.
• Use MRI before biopsy where available to reduce unnecessary biopsies.
• Offer active surveillance for low-risk cancers found by screening.

Why it matters

It moves the evidence on PSA screening from uncertain to a clear mortality benefit, while leaving the harms in place.

Don't overread it

A mortality benefit among men who engage in screening does not by itself make population screening right.

The statistics, in plain English

The review reports high-certainty evidence and a p-value below 0.001 but no rate ratio in the abstract, so the size of the benefit cannot be stated here. Analysing men who actually screened, rather than all those invited, estimates the effect of screening itself but can be influenced by differences between those who accept and decline.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.